Mesoblast Completes Enrollment in Phase 3 Trial for Chronic Low Back Pain Treatment — Mesoblast Limited

Event summary

Mesoblast completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain (CLBP) associated with degenerative disc disease.
The trial's primary endpoint aims to confirm durable pain reduction at 12 months from a single intra-discal injection of rexlemestrocel-L.
Top-line results are expected in mid-CY2027, with the potential for a Biologics License Application (BLA) filing thereafter.
Rexlemestrocel-L has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, enabling priority review.

The big picture

Mesoblast's completion of the Phase 3 trial for rexlemestrocel-L marks a significant step toward potentially launching a blockbuster product in the chronic low back pain market. With over 7 million affected individuals in the U.S. alone and a potential peak revenue of over $10 billion, the success of this trial could position Mesoblast as a key player in the regenerative medicine space. The strategic focus on inflammatory conditions aligns with broader industry trends toward targeted cellular therapies for chronic diseases.

What we're watching

Regulatory Pathway: Whether the RMAT designation will expedite the approval process for rexlemestrocel-L, potentially reducing time to market.
Market Penetration: The pace at which Mesoblast can capture market share in the CLBP space, given the condition's prevalence and unmet needs.
Clinical Efficacy: How the 12-month pain reduction data from the Phase 3 trial compares to the earlier Phase 3 trial, which will be critical for regulatory approval.